Analysis of chronic myeloid leukaemia during deep molecular
response by genomic PCR: a traffic light stratification model
with impact on treatment-free remission

J 2020

Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission

MACHOVA POLAKOVA, Katerina; Hana ZIZKOVA; Jan ZUNA; Eliska MOTLOVA; Lenka HOVORKOVA et al.

Základní údaje

Originální název

Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission

Autoři

Vydání

Leukemia, London, Nature Publishing Group, 2020, 0887-6924

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 11.528

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/20:00116511

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

chronic myeloid leukaemia; genomic PCR

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 8. 4. 2021 07:46, Mgr. Tereza Miškechová

Anotace

V originále

This work investigated patient-specific genomic BCR-ABL1 fusions as markers of measurable residual disease (MRD) in chronic myeloid leukaemia, with a focus on relevance to treatment-free remission (TFR) after achievement of deep molecular response (DMR) on tyrosine kinase inhibitor (TKI) therapy. DNA and mRNA BCR-ABL1 measurements by qPCR were compared in 2189 samples (129 patients) and by digital PCR in 1279 sample (62 patients). A high correlation was found at levels of disease above MR4, but there was a poor correlation for samples during DMR. A combination of DNA and RNA MRD measurements resulted in a better prediction of molecular relapse-free survival (MRFS) after TKI stop (n=17) or scheduled interruption (n=25). At 18 months after treatment cessation, patients with stopped or interrupted TKI therapy who were DNA negative/RNA negative during DMR maintenance (green group) had an MRFS of 80% and 100%, respectively, compared with those who were DNA positive/RNA negative (MRFS=57% and 67%, respectively; yellow group) or DNA positive/RNA positive (MRFS=20% for both cohorts; red group). Thus, we propose a "traffic light" stratification as a TFR predictor based on DNA and mRNA BCR-ABL1 measurements during DMR maintenance before TKI cessation.

Návaznosti

LM2018128, projekt VaV

Název: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Akronym: CZECRIN)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Český národní uzel Evropské sítě infrastruktur klinického výzkumu (CZECRIN)

Citovat

MACHOVA POLAKOVA, Katerina; Hana ZIZKOVA; Jan ZUNA; Eliska MOTLOVA; Lenka HOVORKOVA; Andrea GOTTSCHALK; Ingmar GLAUCHE; Jitka KOBLIHOVA; Pavla PECHERKOVA; Hana KLAMOVA; Marketa STASTNA MARKOVA; Dana SRBOVA; Adela BENESOVA; Vaclava POLIVKOVA; Tomáš JURČEK; Daniela ŽÁČKOVÁ; Jiří MAYER; Thomas ERNST; Francois X. MAHON; Susanne SAUSSELE; Ingo ROEDERVIEW; Nicholas C. P. CROSS a Andreas HOCHHAUS. Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission. Leukemia. London: Nature Publishing Group, 2020, roč. 34, č. 8, s. 2113-2124. ISSN 0887-6924. Dostupné z: https://doi.org/10.1038/s41375-020-0882-1.

@article{1681536,
   author = {Machova Polakova, Katerina and Zizkova, Hana and Zuna, Jan and Motlova, Eliska and Hovorkova, Lenka and Gottschalk, Andrea and Glauche, Ingmar and Koblihova, Jitka and Pecherkova, Pavla and Klamova, Hana and Stastna Markova, Marketa and Srbova, Dana and Benesova, Adela and Polivkova, Vaclava and Jurček, Tomáš and Žáčková, Daniela and Mayer, Jiří and Ernst, Thomas and Mahon, Francois X. and Saussele, Susanne and RoederView, Ingo and Cross, Nicholas C. P. and Hochhaus, Andreas},
   article_location = {London},
   article_number = {8},
   doi = {https://doi.org/10.1038/s41375-020-0882-1},
   keywords = {chronic myeloid leukaemia; genomic PCR},
   language = {eng},
   issn = {0887-6924},
   journal = {Leukemia},
   title = {Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission},
   url = {https://www.nature.com/articles/s41375-020-0882-1#author-information},
   volume = {34},
   year = {2020}
}

TY  - JOUR
ID  - 1681536
AU  - Machova Polakova, Katerina - Zizkova, Hana - Zuna, Jan - Motlova, Eliska - Hovorkova, Lenka - Gottschalk, Andrea - Glauche, Ingmar - Koblihova, Jitka - Pecherkova, Pavla - Klamova, Hana - Stastna Markova, Marketa - Srbova, Dana - Benesova, Adela - Polivkova, Vaclava - Jurček, Tomáš - Žáčková, Daniela - Mayer, Jiří - Ernst, Thomas - Mahon, Francois X. - Saussele, Susanne - RoederView, Ingo - Cross, Nicholas C. P. - Hochhaus, Andreas
PY  - 2020
TI  - Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission
JF  - Leukemia
VL  - 34
IS  - 8
SP  - 2113-2124
EP  - 2113-2124
PB  - Nature Publishing Group
SN  - 08876924
KW  - chronic myeloid leukaemia
KW  - genomic PCR
UR  - https://www.nature.com/articles/s41375-020-0882-1#author-information
L2  - https://www.nature.com/articles/s41375-020-0882-1#author-information
N2  - This work investigated patient-specific genomic BCR-ABL1 fusions as markers of measurable residual disease (MRD) in chronic myeloid leukaemia, with a focus on relevance to treatment-free remission (TFR) after achievement of deep molecular response (DMR) on tyrosine kinase inhibitor (TKI) therapy. DNA and mRNA BCR-ABL1 measurements by qPCR were compared in 2189 samples (129 patients) and by digital PCR in 1279 sample (62 patients). A high correlation was found at levels of disease above MR4, but there was a poor correlation for samples during DMR. A combination of DNA and RNA MRD measurements resulted in a better prediction of molecular relapse-free survival (MRFS) after TKI stop (n=17) or scheduled interruption (n=25). At 18 months after treatment cessation, patients with stopped or interrupted TKI therapy who were DNA negative/RNA negative during DMR maintenance (green group) had an MRFS of 80% and 100%, respectively, compared with those who were DNA positive/RNA negative (MRFS=57% and 67%, respectively; yellow group) or DNA positive/RNA positive (MRFS=20% for both cohorts; red group). Thus, we propose a "traffic light" stratification as a TFR predictor based on DNA and mRNA BCR-ABL1 measurements during DMR maintenance before TKI cessation.
ER  -

MACHOVA POLAKOVA, Katerina; Hana ZIZKOVA; Jan ZUNA; Eliska MOTLOVA; Lenka HOVORKOVA; Andrea GOTTSCHALK; Ingmar GLAUCHE; Jitka KOBLIHOVA; Pavla PECHERKOVA; Hana KLAMOVA; Marketa STASTNA MARKOVA; Dana SRBOVA; Adela BENESOVA; Vaclava POLIVKOVA; Tomáš JURČEK; Daniela ŽÁČKOVÁ; Jiří MAYER; Thomas ERNST; Francois X. MAHON; Susanne SAUSSELE; Ingo ROEDERVIEW; Nicholas C. P. CROSS a Andreas HOCHHAUS. Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission. \textit{Leukemia}. London: Nature Publishing Group, 2020, roč.~34, č.~8, s.~2113-2124. ISSN~0887-6924. Dostupné z: https://doi.org/10.1038/s41375-020-0882-1.

Přehled o publikaci